Lipid-Based Nanoparticles Development Services

As the pharmaceutical and biotechnology industries continue to grow, the demand for innovative drug delivery systems (DDS) is increasing exponentially. The development of lipid nanoparticles (LNPs) is a promising technology that has received much attention. These versatile and customizable carriers have great potential for the effective delivery of a wide range of therapeutic agents from small molecules to biologics.

Protheragen-ING specializes in the development of lipid-based nanoparticles for various applications in the field of drug delivery. With our cutting-edge technology and expertise, we offer comprehensive services tailored to meet your specific needs. Our customized solutions will enable you to maximize the therapeutic potential of your drug candidates, ultimately providing more effective and safer treatments for your patients.

About LNP

LNPs are self-assembling colloidal structures composed of lipids such as phospholipids, cholesterol, and other lipid-like molecules. Conventional liposomes are characterized by a lipid bilayer surrounding an aqueous core. LNPs possess an electron-dense core in which ionizable cationic lipids are organized into anticolloid micelles around the encapsulated genetic material. Their ability to encapsulate and protect fragile drug payloads, coupled with their favorable pharmacokinetic profile and enhanced tissue targeting, make LNPs a preferred choice for a variety of therapeutic interventions.

Fig.1 Lipid nanoparticle nucleic acid carriers.Fig. 1 Lipid nanoparticle nucleic acid carriers: Nucleic acids are organized in antilipid micelles inside the nanoparticles. (Tenchov R, et al. 2021)

Advantages of Lipid-Based Nanoparticles as DDSs

Protheragen-ING's Comprehensive Development Services

We design lipid-based nanoparticle formulations to fit your specific therapeutic payload and delivery requirements. We optimize the formulation design by considering factors such as drug compatibility, stability, release kinetics, and target site.

Our extensive library of lipids and lipid derivatives allows us to select the most appropriate lipid composition for your nanoparticle formulation. Through systematic optimization, we can fine-tune the lipid composition for optimal drug loading, release profile, and stability.

We employ a range of advanced characterization techniques to assess the physicochemical properties of the developed lipid nanoparticles, including particle size analysis, zeta potential measurements, determination of drug encapsulation efficiency, assessment of drug release kinetics, and stability testing.

We offer surface modification services for lipid-based nanoparticles. Some of the common surface modification strategies include targeted modification, stability enhancement, and functionality introduction.

We conduct rigorous in vitro and in vivo studies to evaluate the performance and efficacy of nanoparticles, including cell culture assays to assess cellular uptake and cytotoxicity, as well as animal studies to investigate biodistribution, pharmacokinetics, and therapeutic outcomes.

Fig.2 Approaches for organ specific modifications of LNPs used for RNA delivery.Fig. 2 Approaches for organ specific modifications of LNPs used for RNA delivery. (Żak MM, et al. 2021)

Wide Range of Lipid-Based Nanoparticles

We can develop a wide range of lipid-based nanoparticle formulations based on your specific needs, including:

Preparation Techniques for Lipid-Based Nanoparticles

We utilize advanced lipid nanoparticle preparation technologies to ensure the reproducibility, scalability, and quality of our formulations. Our manufacturing processes follow stringent quality control standards designed to optimize drug encapsulation efficiency, particle size distribution, and stability. Some of the methods we use include:

Contact with us today to unlock the full potential of lipid nanoparticles for pharmaceutical and biotechnology applications. Together, we'll tackle the complexities of drug delivery and drive successful clinical and commercial outcomes for your program.


  1. Tenchov R, et al. (2021). "Lipid Nanoparticles-From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement." ACS Nano, 15(11), 16982-17015.
  2. Żak MM, et al. (2021). "Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery." Pharmaceutics, 13(10), 1675.


Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen-ING. All Rights Reserved.
Member of